Advanced search
Publication Cover
Journal of Chemotherapy Volume 30, 2018 - Issue 5
Submit an article Journal homepage
129
Views
4
CrossRef citations to date
0
Altmetric
Brief Communication

Pulmonary adverse events related to idelalisib therapy: A single centre experience

Caroline MigaultCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France;
,
Delphine LebrunCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France;
,
Olivier ToubasUniversité de Reims Champagne-Ardenne, Faculté de Médecine, EA-4684/SFR CAP-SANTE, Reims, France;
,
Yohan NguyenCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France; ;Université de Reims Champagne-Ardenne, Faculté de Médecine, EA-4684/SFR CAP-SANTE, Reims, France;
,
Aurélien GiltatCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France;
,
Gautier JulienCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France;
,
Dominique ToubasCHU Reims, Laboratoire de Parasitologie Mycologie, Reims, France;
,
François LebargyCHU Reims, Service de Pneumologie, Université Reims Champagne Ardenne, UFR Médecine France, Reims, France;
,
Alain DelmerCHU Reims, Service d'Hématologie Clinique, Université Reims Champagne Ardenne, UFR Médecine, Reims, France
&
Firouzé Bani-SadrCHU Reims, Service de Médecine Interne et Maladies Infectieuses et Tropicales, Reims, France; ;Université de Reims Champagne-Ardenne, Faculté de Médecine, EA-4684/SFR CAP-SANTE, Reims, France; Correspondence[email protected]
 show all
Pages 318-322 | Received 07 Jun 2017, Accepted 20 Aug 2018, Published online: 09 Oct 2018

References

  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
  • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
  • de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: A practical approach. Haematologica. 2017;102(10):1629–1639.
  • Madanat YF, Smith MR, Almasan A, Hill BT. Idelalisib therapy of indolent B-cell malignancies: Chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer Targets Ther. 2016;6:1–6.
  • Haustraete E, Obert J, Diab S, Abbes S, Zini J-M, Valade S, et al. Idelalisib-related pneumonitis. Eur Respir J. 2016;47(4):1280–1283.
  • Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O’Brien SM, et al. Phase 2 study of idelalisib and entospletinib: Pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411–2415.
  • Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood. 2016;128(18):2199–2205.
  • O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–2694.
  • Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, et al. Management of adverse events associated with idelalisib treatment: Expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–2786.
  • Albiges L, Chamming’s F, Duclos B, Stern M, Motzer RJ, Ravaud A, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23(8):1943–1953.
  • Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100(12):1495–1507.
  • Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348(26):2690–2691; discussion 2690–2691.
  • Naqibullah M, Shaker SB, Bach KS, Bendstrup E. Rituximab-induced interstitial lung disease: Five case reports. Eur Clin Respir J [Internet]. 2015 [cité 26 août 2016];2. Disponible sur: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629765/
  • Weidner A-S, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, et al. Idelalisib-associated Colitis: Histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661–1667.
  • Balagoni H, Chaudhari D, Reddy C, Young M. Idelalisib: A rare cause of enterocolitis. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2016;29(2):233–235.
  • Toquet S, Nguyen Y, Sabbagh A, Djerada Z, Boulagnon C, Bani-Sadr F. Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis. Jt Bone Spine Rev Rhum. 2016;83(2):217–219.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.